Drug Profile
Zotatifin - eFFECTOR Therapeutics
Alternative Names: eFT 226Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator eFFECTOR Therapeutics
- Developer eFFECTOR Therapeutics; Quantitative Biosciences Institute
- Class Amines; Antineoplastics; Antivirals; Benzonitrile; Cyclopentanes; Furans; Pyridines; Small molecules
- Mechanism of Action Eukaryotic initiation factor-4A inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Non-small cell lung cancer
- Phase I COVID 2019 infections
- No development reported Lymphoma
Most Recent Events
- 25 Mar 2024 eFFECTOR Therapeutics announces its plan to meet with the US FDA in the second half of 2024
- 25 Mar 2024 Effector Therapeutics plans a clinical trial in Breast cancer
- 08 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Breast cancer and Non-small cell lung cancer released by Effector Therapeutics